AZRX vs. ENLV, DRRX, LPCN, NNVC, JAN, BIOR, ACST, UBX, ONCT, and THTX
Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include Enlivex Therapeutics (ENLV), DURECT (DRRX), Lipocine (LPCN), NanoViricides (NNVC), JanOne (JAN), Biora Therapeutics (BIOR), Acasti Pharma (ACST), Unity Biotechnology (UBX), Oncternal Therapeutics (ONCT), and Theratechnologies (THTX). These companies are all part of the "medical" sector.
Enlivex Therapeutics (NASDAQ:ENLV) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Enlivex Therapeutics is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Enlivex Therapeutics had 2 more articles in the media than AzurRx BioPharma. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 0 mentions for AzurRx BioPharma. AzurRx BioPharma's average media sentiment score of 1.18 beat Enlivex Therapeutics' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the media.
AzurRx BioPharma received 176 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 74.26% of users gave AzurRx BioPharma an outperform vote.
Enlivex Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
Enlivex Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 398.22%. Given AzurRx BioPharma's higher possible upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than AzurRx BioPharma.
1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
AzurRx BioPharma's return on equity of -71.00% beat Enlivex Therapeutics' return on equity.
Summary
Enlivex Therapeutics beats AzurRx BioPharma on 10 of the 14 factors compared between the two stocks.
Get AzurRx BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AzurRx BioPharma Competitors List
Related Companies and Tools
